,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'enhertu']
a new standard for her-2 low ( hormone receptor + and triple negative) advanced #breastcancer #asco22 t-dxd - enhertu 
Prof. & Chair Dept. of Heme and Oncology @ClevelandClinic @NRGonc Deputy Editor @JCOOP_ASCO Tweets are mine. No act of #Kindness is ever wasted #CleClinicCancer